Alector, Inc.
US ˙ NasdaqGS ˙ US0144421072

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Terrance Mcguire. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Terrance Mcguire har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:SEER / Seer, Inc. Director 112.066
Director 573.062
US:IVVD / Invivyd, Inc. Director 3.066.757
US:CYCN / Cyclerion Therapeutics, Inc. Director 5.552
US:ALEC / Alector, Inc. Director, 10% Owner 10.853.817
US:LYRA / Lyra Therapeutics, Inc. 10% Owner 0
US:PHR / Phreesia, Inc. 10% Owner 31.015
US:PULM / Pulmatrix, Inc. Director 15.000
US:IRWD / Ironwood Pharmaceuticals, Inc. Director 73.630
US:ASNS / Actelis Networks, Inc. Director 10.000
US:XLRN / Acceleron Pharma Inc Director 7.500
US:TRVN / Trevena, Inc. 10% Owner 36.369
US:BIND / BIND Therapeutics, Inc. 10% Owner 0
US:ALIM / Alimera Sciences, Inc. 10% Owner 3.090.769
US:ALNY / Alnylam Pharmaceuticals, Inc. 10% Owner 37.074
SG:5BI / Polaris Ltd. 10% Owner 37.178
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Terrance Mcguire. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb ALEC / Alector, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ALEC / Alector, Inc. Insider Trades
Insidersalg ALEC / Alector, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

ALEC / Alector, Inc. Insider Trades
Insiderkøb CYCN / Cyclerion Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-06-03 CYCN MCGUIRE TERRANCE 92.831 3,1200 4.642 62,4000 289.633 11 1716 7.674.324 2.649,68
2021-06-03 CYCN MCGUIRE TERRANCE 3.322 3,1200 166 62,4000 10.365
2019-04-08 CYCN MCGUIRE TERRANCE 604.482 16,0000 30.224 320,0000 9.671.712
2019-04-08 CYCN MCGUIRE TERRANCE 21.635 16,0000 1.082 320,0000 346.160

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CYCN / Cyclerion Therapeutics, Inc. Insider Trades
Insidersalg CYCN / Cyclerion Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2023-08-09 CYCN MCGUIRE TERRANCE 8 3,3950 8 3,3950 27 238 0.0000 -27 -100,00

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

CYCN / Cyclerion Therapeutics, Inc. Insider Trades
Insiderkøb IRWD / Ironwood Pharmaceuticals, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IRWD / Ironwood Pharmaceuticals, Inc. Insider Trades
Insidersalg IRWD / Ironwood Pharmaceuticals, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2013-11-07 IRWD MCGUIRE TERRANCE 57 9,1100 57 9,1100 519 5 7.9449 -66 -12,74
2013-11-07 IRWD MCGUIRE TERRANCE 2.026 9,1100 2.026 9,1100 18.457

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IRWD / Ironwood Pharmaceuticals, Inc. Insider Trades
Insiderkøb IVVD / Invivyd, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2021-08-10 ADGI MCGUIRE TERRANCE 267.769 17,0000 267.769 17,0000 4.552.073 37 56.08 10.464.413 229,88
2021-08-10 ADGI MCGUIRE TERRANCE 5.219 17,0000 5.219 17,0000 88.723
2021-08-10 ADGI MCGUIRE TERRANCE 1.834 17,0000 1.834 17,0000 31.178
2021-08-10 ADGI MCGUIRE TERRANCE 2.678 17,0000 2.678 17,0000 45.526
2021-08-10 ADGI MCGUIRE TERRANCE 45.000 17,0000 45.000 17,0000 765.000
2021-08-10 ADGI MCGUIRE TERRANCE 177.500 17,0000 177.500 17,0000 3.017.500

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IVVD / Invivyd, Inc. Insider Trades
Insidersalg IVVD / Invivyd, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2024-12-31 IVVD MCGUIRE TERRANCE 103.474 0,4455 103.474 0,4455 46.098 31 0.3577 -9.084 -19,71
2024-12-30 IVVD MCGUIRE TERRANCE 86.545 0,4828 86.545 0,4828 41.784
2024-12-27 IVVD MCGUIRE TERRANCE 83.744 0,5212 83.744 0,5212 43.647
2024-12-26 IVVD MCGUIRE TERRANCE 83.817 0,5436 83.817 0,5436 45.563
2024-12-24 IVVD MCGUIRE TERRANCE 68.161 0,5062 68.161 0,5062 34.503
2024-12-23 IVVD MCGUIRE TERRANCE 75.776 0,4497 75.776 0,4497 34.076
2024-12-20 IVVD MCGUIRE TERRANCE 119.805 0,4234 119.805 0,4234 50.725
2024-12-19 IVVD MCGUIRE TERRANCE 152.067 0,4337 152.067 0,4337 65.951
2024-12-18 IVVD MCGUIRE TERRANCE 74.764 0,4693 74.764 0,4693 35.087
2024-12-17 IVVD MCGUIRE TERRANCE 97.410 0,4800 97.410 0,4800 46.757
2024-12-16 IVVD MCGUIRE TERRANCE 65.359 0,4668 65.359 0,4668 30.510
2024-12-12 IVVD MCGUIRE TERRANCE 125.000 0,5830 125.000 0,5830 72.875
2024-12-11 IVVD MCGUIRE TERRANCE 160.400 0,5911 160.400 0,5911 94.812
2024-12-10 IVVD MCGUIRE TERRANCE 175.000 0,5886 175.000 0,5886 103.005
2024-12-09 IVVD MCGUIRE TERRANCE 150.000 0,6104 150.000 0,6104 91.560
2024-05-29 IVVD MCGUIRE TERRANCE 112.381 1,6602 112.381 1,6602 186.575

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IVVD / Invivyd, Inc. Insider Trades
Insiderkøb LYRA / Lyra Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 60.308 16,0000 1.206 800,0000 964.928 0 16.65 -944.848 -97,92
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 1.176 16,0000 24 800,0000 18.816
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 603 16,0000 12 800,0000 9.648
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 413 16,0000 8 800,0000 6.608

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LYRA / Lyra Therapeutics, Inc. Insider Trades
Insidersalg LYRA / Lyra Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 9.334 16,0000 187 800,0000 149.344 365 8.44 -147.774 -98,95
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 182 16,0000 4 800,0000 2.912
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 94 16,0000 2 800,0000 1.504
2020-05-05 LYRA Polaris Venture Management Co. V, L.L.C. 64 16,0000 1 800,0000 1.024

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

LYRA / Lyra Therapeutics, Inc. Insider Trades
Insiderkøb PHR / Phreesia, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PHR / Phreesia, Inc. Insider Trades
Insidersalg PHR / Phreesia, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2019-12-17 PHR Polaris Venture Management Co. V, L.L.C. 344.599 24,4790 344.599 24,4790 8.435.439 92 16.59 -2.718.541 -32,23
2019-12-17 PHR Polaris Venture Management Co. V, L.L.C. 6.716 24,4790 6.716 24,4790 164.401
2019-12-17 PHR Polaris Venture Management Co. V, L.L.C. 2.360 24,4790 2.360 24,4790 57.770
2019-12-17 PHR Polaris Venture Management Co. V, L.L.C. 3.446 24,4790 3.446 24,4790 84.355
2019-07-22 PHR Polaris Venture Management Co. V, L.L.C. 382.887 18,0000 382.887 18,0000 6.891.966
2019-07-22 PHR Polaris Venture Management Co. V, L.L.C. 7.462 18,0000 7.462 18,0000 134.316
2019-07-22 PHR Polaris Venture Management Co. V, L.L.C. 2.622 18,0000 2.622 18,0000 47.196
2019-07-22 PHR Polaris Venture Management Co. V, L.L.C. 3.828 18,0000 3.828 18,0000 68.904

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PHR / Phreesia, Inc. Insider Trades
Insiderkøb PULM / Pulmatrix, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2018-04-03 PULM MCGUIRE TERRANCE 345.551 23.037 69 120
2018-04-03 PULM MCGUIRE TERRANCE 6.478 432
2018-04-03 PULM MCGUIRE TERRANCE 769.989 51.333
2018-04-03 PULM MCGUIRE TERRANCE 15.007 1.000
2018-04-03 PULM MCGUIRE TERRANCE 5.275 352
2018-04-03 PULM MCGUIRE TERRANCE 7.700 513
2015-06-15 PULM MCGUIRE TERRANCE 32.059 6,8750 2.959 74,4792 220.406
2015-06-15 PULM MCGUIRE TERRANCE 601 6,8750 55 74,4792 4.132
2015-06-15 PULM MCGUIRE TERRANCE 71.438 6,8750 6.594 74,4792 491.136
2015-06-15 PULM MCGUIRE TERRANCE 489 6,8750 45 74,4792 3.362
2015-06-15 PULM MCGUIRE TERRANCE 714 6,8750 66 74,4792 4.909
2015-06-15 PULM MCGUIRE TERRANCE 1.392 6,8750 128 74,4792 9.570
2015-06-15 PULM MCGUIRE TERRANCE 71.439 6,8750 6.594 74,4792 491.143
2015-06-15 PULM MCGUIRE TERRANCE 490 6,8750 45 74,4792 3.369
2015-06-15 PULM MCGUIRE TERRANCE 715 6,8750 66 74,4792 4.916
2015-06-15 PULM MCGUIRE TERRANCE 1.392 6,8750 128 74,4792 9.570

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PULM / Pulmatrix, Inc. Insider Trades
Insidersalg PULM / Pulmatrix, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PULM / Pulmatrix, Inc. Insider Trades
Insiderkøb SEER / Seer, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2020-12-08 SEER MCGUIRE TERRANCE 78.947 19,0000 78.947 19,0000 1.499.993 43 84.06 5.136.292 342,42

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SEER / Seer, Inc. Insider Trades
Insidersalg SEER / Seer, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

SEER / Seer, Inc. Insider Trades
Insiderkøb TRVN / Trevena, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ALEC / Alector, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2014-02-05 TRVN Polaris Venture Management Co. V, L.L.C. 472.405 7,0000 18.896 175,0000 3.306.835 28 241 1.247.101 37,71

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TRVN / Trevena, Inc. Insider Trades
Insidersalg TRVN / Trevena, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ALEC / Alector, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
2014-08-14 TRVN Polaris Venture Management Co. V, L.L.C. 35.415 6,0400 1.417 151,0000 213.907 116 99.5 -73.014 -34,13
2014-08-14 TRVN Polaris Venture Management Co. V, L.L.C. 690 6,0400 28 151,0000 4.168
2014-08-14 TRVN Polaris Venture Management Co. V, L.L.C. 243 6,0400 10 151,0000 1.468
2014-08-14 TRVN Polaris Venture Management Co. V, L.L.C. 354 6,0400 14 151,0000 2.138
2014-08-13 TRVN Polaris Venture Management Co. V, L.L.C. 5.500 6,1200 220 153,0000 33.660
2014-08-13 TRVN Polaris Venture Management Co. V, L.L.C. 107 6,1200 4 153,0000 655
2014-08-13 TRVN Polaris Venture Management Co. V, L.L.C. 38 6,1200 2 153,0000 233
2014-08-13 TRVN Polaris Venture Management Co. V, L.L.C. 55 6,1200 2 153,0000 337

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

TRVN / Trevena, Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Terrance Mcguire som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-07-09 2025-07-07 4 SEER Seer, Inc.
Class A Common Stock
A - Award 20.500 112.066 22,39
2025-04-07 2025-04-07 4 TECX Tectonic Therapeutic, Inc.
Common Stock
S - Sale -500.000 573.062 -46,60 17,10 -8.550.000 9.799.360
2024-12-31 2024-12-31 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -103.474 3.066.757 -3,26 0,45 -46.098 1.366.240
2024-12-31 2024-12-30 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -86.545 3.170.231 -2,66 0,48 -41.784 1.530.588
2024-12-31 2024-12-27 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -83.744 3.256.776 -2,51 0,52 -43.647 1.697.432
2024-12-26 2024-12-26 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -83.817 3.340.520 -2,45 0,54 -45.563 1.815.907
2024-12-26 2024-12-24 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -68.161 3.424.337 -1,95 0,51 -34.503 1.733.399
2024-12-26 2024-12-23 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -75.776 3.492.498 -2,12 0,45 -34.076 1.570.576
2024-12-26 2024-12-20 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -119.805 3.568.274 -3,25 0,42 -50.725 1.510.807
2024-12-19 2024-12-19 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -152.067 3.688.079 -3,96 0,43 -65.951 1.599.520
2024-12-19 2024-12-18 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -74.764 3.840.146 -1,91 0,47 -35.087 1.802.181
2024-12-19 2024-12-17 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -97.410 3.914.910 -2,43 0,48 -46.757 1.879.157
2024-12-16 2024-12-16 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -65.359 4.012.320 -1,60 0,47 -30.510 1.872.951
2024-12-16 2024-12-12 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -125.000 4.077.679 -2,97 0,58 -72.875 2.377.287
2024-12-11 2024-12-11 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -160.400 4.202.679 -3,68 0,59 -94.812 2.484.204
2024-12-11 2024-12-10 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -175.000 4.363.079 -3,86 0,59 -103.005 2.568.108
2024-12-11 2024-12-09 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -150.000 4.538.079 -3,20 0,61 -91.560 2.770.043
2024-06-24 2024-06-20 4 TECX Tectonic Therapeutic, Inc.
Common Stock
A - Award 64.652 64.652
2024-06-24 2024-06-20 4 TECX Tectonic Therapeutic, Inc.
Common Stock
A - Award 20.262 20.262
2024-06-24 2024-06-20 4 TECX Tectonic Therapeutic, Inc.
Common Stock
A - Award 1.073.062 1.073.062
2024-06-14 2024-06-12 4 SEER Seer, Inc.
Class A Common Stock
A - Award 58.178 91.566 174,25
2024-05-31 2024-05-29 4 IVVD Invivyd, Inc.
Common Stock
S - Sale -112.381 4.688.079 -2,34 1,66 -186.575 7.783.149
2023-12-04 2023-11-30 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
A - Award 5.000 5.552 905,80
2023-09-13 2023-09-11 4 ALEC Alector, Inc.
Common Stock
S - Sale -500.000 10.853.817 -4,40 6,00 -3.000.000 65.122.902
2023-08-24 2023-08-22 4 ALEC Alector, Inc.
Common Stock
J - Other 13.133 39.399 50,00
2023-08-24 2023-08-22 4 ALEC Alector, Inc.
Common Stock
J - Other -98.533 0 -100,00
2023-08-24 2023-08-22 4 ALEC Alector, Inc.
Common Stock
J - Other 98.533 98.553 492.665,00
2023-08-24 2023-08-22 4 ALEC Alector, Inc.
Common Stock
J - Other 6.429 54.996 13,24
2023-08-24 2023-08-22 4 ALEC Alector, Inc.
Common Stock
J - Other -500.000 11.353.817 -4,22
2023-08-11 2023-08-09 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
S - Sale -8 0 -100,00 3,40 -27
2023-06-16 2023-06-14 4 SEER Seer, Inc.
Class A Common Stock
A - Award 23.443 33.388 235,73
2023-06-15 2023-06-14 4 ALEC Alector, Inc.
Common Stock
A - Award 26.250 48.567 117,62
2022-11-18 2022-11-16 4 ALEC Alector, Inc.
Common Stock
J - Other 13.133 26.266 100,00
2022-11-18 2022-11-16 4 ALEC Alector, Inc.
Common Stock
J - Other -98.533 0 -100,00
2022-11-18 2022-11-16 4 ALEC Alector, Inc.
Common Stock
J - Other 98.533 98.553 492.665,00
2022-11-18 2022-11-16 4 ALEC Alector, Inc.
Common Stock
J - Other 6.429 22.317 40,46
2022-11-18 2022-11-16 4 ALEC Alector, Inc.
Common Stock
J - Other -500.000 11.853.817 -4,05
2022-06-21 2022-06-16 4 ALEC Alector, Inc.
Common Stock
A - Award 9.459 15.888 147,13
2022-06-17 2022-06-15 4 SEER Seer, Inc.
Class A Common Stock
A - Award 9.945 9.945
2021-12-23 2021-12-21 4 ALEC Alector, Inc.
Common Stock
J - Other 13.133 13.133
2021-12-23 2021-12-21 4 ALEC Alector, Inc.
Common Stock
J - Other -98.533 0 -100,00
2021-12-23 2021-12-21 4 ALEC Alector, Inc.
Common Stock
J - Other 98.533 98.533
2021-12-23 2021-12-21 4 ALEC Alector, Inc.
Common Stock
J - Other 6.429 6.429
2021-12-23 2021-12-21 4 ALEC Alector, Inc.
Common Stock
J - Other -500.000 12.353.817 -3,89
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series C Preferred
C - Conversion -64.032 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -32.016 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -1.235 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -846 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -2.409 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -123.574 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -44.076 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -850 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -583 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1.658 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -85.061 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -875.000 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -3.619 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -2.479 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -7.052 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -361.850 0 -100,00
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
P - Purchase 177.500 497.660 55,44 17,00 3.017.500 8.460.220
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
C - Conversion 320.160 320.160
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
P - Purchase 45.000 4.800.460 0,95 17,00 765.000 81.607.820
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
C - Conversion 4.755.460 4.755.460
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
P - Purchase 2.678 31.198 9,39 17,00 45.526 530.366
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
C - Conversion 28.520 28.520
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
P - Purchase 1.834 21.374 9,39 17,00 31.178 363.358
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
C - Conversion 19.540 19.540
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
P - Purchase 5.219 60.814 9,39 17,00 88.723 1.033.838
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
C - Conversion 55.595 55.595
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
P - Purchase 267.769 3.120.194 9,39 17,00 4.552.073 53.043.298
2021-08-12 2021-08-10 4 ADGI Adagio Therapeutics, Inc.
Common Stock
C - Conversion 2.852.425 2.852.425
2021-08-09 2021-08-05 4 ADGI Adagio Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 35.593 35.593
2021-06-28 2021-06-24 4 CYCN Cyclerion Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 10.000 10.000
2021-06-22 2021-06-17 4 ALEC Alector, Inc.
Stock Option (right to buy)
A - Award 25.709 25.709
2021-06-22 2021-06-17 4 SEER Seer, Inc.
Stock Option (right to buy)
A - Award 15.000 15.000
2021-06-07 2021-06-03 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
P - Purchase 3.322 24.957 15,35 3,12 10.365 77.866
2021-06-07 2021-06-03 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
P - Purchase 92.831 697.313 15,36 3,12 289.633 2.175.617
2020-12-11 2020-12-03 4 SEER Seer, Inc.
Stock Option (right to buy)
A - Award 18.691 18.691
2020-12-09 2020-12-08 4 SEER Seer, Inc.
Series A Convertible Preferred Stock
C - Conversion -51.457 0 -100,00
2020-12-09 2020-12-08 4 SEER Seer, Inc.
Class A Common Stock
P - Purchase 78.947 78.947 19,00 1.499.993 1.499.993
2020-12-09 2020-12-08 4 SEER Seer, Inc.
Class A Common Stock
C - Conversion 51.457 210.982 32,26
2020-12-03 3 SEER Seer, Inc.
Class A Common Stock
159.525
2020-06-25 2020-06-23 4 ALEC Alector, Inc.
Common Stock
S - Sale -4.377 12.853.817 -0,03 31,54 -138.063 405.445.379
2020-06-18 2020-06-16 4 CYCN Cyclerion Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 10.000 10.000
2020-05-13 2020-05-11 4 ALEC Alector, Inc.
Stock Option (right to buy)
A - Award 19.274 19.274
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants
X - Other -118 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants
X - Other -173 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants
X - Other -337 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants
X - Other -17.304 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock
C - Conversion -13.625 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock
C - Conversion -19.890 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock
C - Conversion -38.765 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock
C - Conversion -1.988.991 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -43.966 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -64.183 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -125.094 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock
C - Conversion -6.418.387 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock
C - Conversion -52.700 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock
C - Conversion -76.934 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock
C - Conversion -149.944 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-4 Convertible Preferred Stock
C - Conversion -7.693.406 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -58.980 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -86.101 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -167.809 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-3 Convertible Preferred Stock
C - Conversion -8.610.081 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -22.580 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -32.961 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -64.237 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -3.296.014 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock
C - Conversion -42.941 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock
C - Conversion -62.687 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock
C - Conversion -122.177 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series A-1/C Convertible Preferred Stock
C - Conversion -6.268.687 0 -100,00
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
P - Purchase 413 7.274 6,02 16,00 6.608 116.384
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
P - Purchase 603 10.618 6,02 16,00 9.648 169.888
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
P - Purchase 1.176 20.701 6,02 16,00 18.816 331.216
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
P - Purchase 60.308 1.062.259 6,02 16,00 964.928 16.996.144
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
S - Sale -64 6.861 -0,92 16,00 -1.024 109.776
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
X - Other 118 6.925 1,73 8,63 1.018 59.763
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
S - Sale -94 10.015 -0,93 16,00 -1.504 160.240
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
X - Other 173 10.109 1,74 8,63 1.493 87.241
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
S - Sale -182 19.525 -0,92 16,00 -2.912 312.400
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
X - Other 337 19.707 1,74 8,63 2.908 170.071
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
S - Sale -9.334 1.001.951 -0,92 16,00 -149.344 16.031.216
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
X - Other 17.304 1.011.285 1,74 8,63 149.334 8.727.390
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
C - Conversion 6.807 6.807
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
C - Conversion 9.936 9.936
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
C - Conversion 19.370 19.370
2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock
C - Conversion 993.981 993.981
2019-12-18 2019-12-17 4 PHR Phreesia, Inc.
Common Stock
S - Sale -3.446 31.015 -10,00 24,48 -84.355 759.216
2019-12-18 2019-12-17 4 PHR Phreesia, Inc.
Common Stock
S - Sale -2.360 21.245 -10,00 24,48 -57.770 520.056
2019-12-18 2019-12-17 4 PHR Phreesia, Inc.
Common Stock
S - Sale -6.716 60.446 -10,00 24,48 -164.401 1.479.658
2019-12-18 2019-12-17 4 PHR Phreesia, Inc.
Common Stock
S - Sale -344.599 3.101.386 -10,00 24,48 -8.435.439 75.918.828
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Junior Convertible Preferred Stock
C - Conversion -84.134 0 -100,00
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Junior Convertible Preferred Stock
C - Conversion -57.631 0 -100,00
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Junior Convertible Preferred Stock
C - Conversion -163.973 0 -100,00
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Junior Convertible Preferred Stock
C - Conversion -8.413.256 0 -100,00
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
S - Sale -3.828 34.461 -10,00 18,00 -68.904 620.298
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
S - Sale -2.622 23.605 -10,00 18,00 -47.196 424.890
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
S - Sale -7.462 67.162 -10,00 18,00 -134.316 1.208.916
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
S - Sale -382.887 3.445.985 -10,00 18,00 -6.891.966 62.027.730
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
C - Conversion 38.289 38.289
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
C - Conversion 26.227 26.227
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
C - Conversion 74.624 74.624
2019-07-24 2019-07-22 4 PHR Phreesia, Inc.
Common Stock
C - Conversion 3.828.872 3.828.872
2019-06-04 2019-06-01 4 CYCN Cyclerion Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 10.000 10.000
2019-05-20 2019-05-16 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 15.000 15.000
2019-05-14 2019-05-10 4 ALEC Alector, Inc.
Stock Option (right to buy)
A - Award 20.000 20.000
2019-04-10 2019-04-08 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
P - Purchase 21.635 21.635 16,00 346.160 346.160
2019-04-10 2019-04-08 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
P - Purchase 604.482 604.482 16,00 9.671.712 9.671.712
2019-04-03 2019-04-01 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
D - Sale to Issuer -4.056 73.630 -5,22
2019-04-03 2019-04-01 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
A - Award 6.911 6.911
2019-04-03 2019-04-01 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
A - Award 162 162
2019-04-03 2019-04-01 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
A - Award 3.279 3.279
2019-04-03 2019-04-01 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
A - Award 7.768 7.768
2019-03-19 2019-03-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 183 77.686 0,24
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Series E Preferred Stock
C - Conversion -527.597 0 -100,00
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Series D Preferred Stock
C - Conversion -1.246.883 0 -100,00
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Series C Preferred Stock
C - Conversion -2.808.989 0 -100,00
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Series B Preferred Stock
C - Conversion -2.500.000 0 -100,00
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Series A-2 Preferred Stock
C - Conversion -5.274.725 0 -100,00
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Series A-1 Preferred Stock
C - Conversion -500.000 0 -100,00
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Common Stock
C - Conversion 527.597 12.858.194 4,28
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Common Stock
C - Conversion 1.246.883 12.330.597 11,25
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Common Stock
C - Conversion 2.808.989 11.083.714 33,95
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Common Stock
C - Conversion 2.500.000 8.274.725 43,29
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Common Stock
C - Conversion 5.274.725 5.774.725 1.054,94
2019-02-13 2019-02-11 4 ALEC Alector, Inc.
Common Stock
C - Conversion 500.000 500.000
2019-01-03 2018-12-31 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 40.000 69.117 137,38
2019-01-03 2018-12-31 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
J - Other -40.000 0 -100,00
2018-12-18 2018-12-14 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 212 77.503 0,27
2018-09-18 2018-09-14 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 136 77.291 0,18
2018-06-19 2018-06-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 135 77.155 0,18
2018-06-07 2018-06-05 4 ASNS Arsanis, Inc.
Stock Option (right to buy)
A - Award 10.000 10.000
2018-06-06 2018-06-05 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 124.000 124.000
2018-06-04 2018-05-31 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 16.223 77.020 26,68
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series A Warrant (right to buy)
P - Purchase 7.700 7.700
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series B Warrant (right to buy)
P - Purchase 7.700 7.700
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series A Warrant (right to buy)
P - Purchase 5.275 5.275
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series B Warrant (right to buy)
P - Purchase 5.275 5.275
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series A Warrant (right to buy)
P - Purchase 15.007 15.007
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series B Warrant (right to buy)
P - Purchase 15.007 15.007
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series A Warrant (right to buy)
P - Purchase 769.989 769.989
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series B Warrant (right to buy)
P - Purchase 769.989 769.989
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series A Warrant (right to buy)
P - Purchase 6.478 6.478
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series B Warrant (right to buy)
P - Purchase 6.478 6.478
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series A Warrant (right to buy)
P - Purchase 345.551 345.551
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Series B Warrant (right to buy)
P - Purchase 345.551 345.551
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 7.700 34.587 28,64
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 5.275 23.875 28,36
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 15.007 67.729 28,46
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 769.989 3.468.190 28,54
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 6.478 29.178 28,54
2018-04-05 2018-04-03 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 345.551 1.556.676 28,53
2018-03-19 2018-03-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 162 60.797 0,27
2018-03-08 2017-11-15 4/A ASNS Arsanis, Inc.
Common Stock (right to buy)
A - Award 25.000 25.000
2017-12-19 2017-12-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 159 60.635 0,26
2017-12-01 2017-11-15 4 ASNS Arsanis, Inc.
Stock Option (right to buy)
A - Award 7.324 7.324
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -21.537 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -14.752 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -41.976 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series D Convertible Preferred Stock
C - Conversion -2.153.746 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock
C - Conversion -2.213 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock
C - Conversion -1.516 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock
C - Conversion -4.315 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series C Convertible Preferred Stock
C - Conversion -221.638 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock
C - Conversion -7.108 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock
C - Conversion -4.869 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock
C - Conversion -13.854 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series B Convertible Preferred Stock
C - Conversion -710.817 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -6.801 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -4.659 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -13.256 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-2 Convertible Preferred Stock
C - Conversion -680.130 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -643 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -441 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -1.254 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Series A-1 Convertible Preferred Stock
C - Conversion -64.329 0 -100,00
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
P - Purchase 4.825 18.031 36,54 10,00 48.250 180.310
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
P - Purchase 3.305 12.351 36,54 10,00 33.050 123.510
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
P - Purchase 9.403 35.146 36,53 10,00 94.030 351.460
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
P - Purchase 482.467 1.803.429 36,52 10,00 4.824.670 18.034.290
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 6.310 13.206 91,50
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 4.322 9.046 91,49
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 12.298 25.743 91,47
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 631.041 1.320.962 91,47
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 1.102 6.896 19,02
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 755 4.724 19,02
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 2.150 13.445 19,03
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 110.312 689.921 19,03
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 3.173 5.794 121,06
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 2.173 3.969 120,99
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 6.185 11.295 121,04
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 317.376 579.609 121,03
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 2.433 2.621 1.294,15
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 1.667 1.796 1.292,25
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 4.743 5.110 1.292,37
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 243.385 262.233 1.291,30
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 188 188
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 129 129
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 367 367
2017-11-20 2017-11-20 4 ASNS Arsanis, Inc.
Common Stock
C - Conversion 18.848 18.848
2017-09-19 2017-09-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 153 60.476 0,25
2017-06-19 2017-06-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 142 60.323 0,24
2017-06-02 2017-05-31 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 15.625 60.181 35,07
2017-03-22 2017-03-20 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 4.400 4.400
2017-03-16 2017-03-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 142 44.556 0,32
2017-03-14 2017-03-02 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 7.500 7.500
2017-03-14 2017-03-02 4 XLRN ACCELERON PHARMA INC
Common Stock
A - Award 1.250 1.250
2016-12-22 2016-12-21 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other 2.190 3.814 134,85
2016-12-22 2016-12-21 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other -747.127 0 -100,00
2016-12-19 2016-12-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 161 44.414 0,36
2016-12-09 2016-12-08 4 XLRN ACCELERON PHARMA INC
Common Stock
S - Sale -643 747.127 -0,09 30,96 -19.907 23.131.052
2016-12-09 2016-12-08 4 XLRN ACCELERON PHARMA INC
Common Stock
S - Sale -34.285 744.386 -4,40 30,96 -1.061.464 23.046.191
2016-12-09 2016-12-07 4 XLRN ACCELERON PHARMA INC
Warrant (Right to Buy)
X - Other -3.384 0 -100,00
2016-12-09 2016-12-07 4 XLRN ACCELERON PHARMA INC
Warrant (Right to Buy)
X - Other -180.518 0 -100,00
2016-12-09 2016-12-07 4 XLRN ACCELERON PHARMA INC
Common Stock
X - Other 3.384 747.770 0,45 5,88 19.898 4.396.888
2016-12-09 2016-12-07 4 XLRN ACCELERON PHARMA INC
Common Stock
X - Other 180.518 778.671 30,18 5,88 1.061.446 4.578.585
2016-11-21 2016-11-18 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other 1.624 1.624
2016-11-21 2016-11-18 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other -6.980 598.153 -1,15
2016-11-21 2016-11-17 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other -693.020 605.133 -53,39
2016-09-19 2016-09-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 166 44.253 0,38
2016-06-17 2016-06-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 196 44.087 0,45
2016-06-03 2016-06-01 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 23.674 43.891 117,10
2016-03-17 2016-03-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 239 20.217 1,20
2016-03-07 2016-03-03 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 10.000 10.000
2016-02-25 2016-02-03 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 8.800 8.800
2015-12-16 2015-12-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 227 19.978 1,15
2015-09-16 2015-09-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 217 19.751 1,11
2015-08-26 2015-08-17 4/A XLRN ACCELERON PHARMA INC
Common Stock
S - Sale -407.259 1.298.153 -23,88 30,25 -12.319.585 39.269.128
2015-08-19 2015-08-17 4 XLRN ACCELERON PHARMA INC
Common Stock
S - Sale -407.259 1.303.232 -23,81 30,25 -12.319.585 39.422.768
2015-06-25 2015-06-24 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 1.108 1.108
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 15.264 15.264
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 7.832 7.832
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 5.365 5.365
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 783.128 783.128
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 6.589 6.589
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 351.448 351.448
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Common Stock
P - Purchase 1.392 52.722 2,71 6,88 9.570 362.464
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Common Stock
P - Purchase 715 26.887 2,73 6,88 4.916 184.848
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Common Stock
P - Purchase 490 18.600 2,71 6,88 3.369 127.875
2015-06-25 2015-06-15 4/A PULM Pulmatrix, Inc.
Common Stock
P - Purchase 71.439 2.698.201 2,72 6,88 491.143 18.550.132
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 17.710 17.710
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 15.264 15.264
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 7.832 7.832
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 5.365 5.365
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 783.128 783.128
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 6.589 6.589
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Warrants to Purchase Common Stock
A - Award 351.448 351.448
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 1.392 52.692 2,71 6,88 9.570 362.258
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
A - Award 51.330 51.330
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 714 26.886 2,73 6,88 4.909 184.841
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
A - Award 26.172 26.172
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 489 18.599 2,70 6,88 3.362 127.868
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
A - Award 18.110 18.110
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 71.438 2.698.200 2,72 6,88 491.136 18.550.125
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
A - Award 2.626.762 2.626.762
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 601 22.700 2,72 6,88 4.132 156.062
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
A - Award 22.099 22.099
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
P - Purchase 32.059 1.211.125 2,72 6,88 220.406 8.326.484
2015-06-17 2015-06-15 4 PULM Pulmatrix, Inc.
Common Stock
A - Award 1.179.066 1.179.066
2015-06-16 2015-06-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 63 19.534 0,32
2015-06-05 2015-06-03 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 16.556 19.471 567,96
2015-06-03 2014-12-11 4/A XLRN ACCELERON PHARMA INC
Common Stock
J - Other -407.256 2.214.482 -15,53
2015-06-03 2015-05-13 4/A XLRN ACCELERON PHARMA INC
Common Stock
J - Other -503.991 1.710.491 -22,76
2015-05-26 2015-05-20 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other -5.079 1.705.412 -0,30
2015-05-13 2015-05-13 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other -503.991 2.117.747 -19,22
2015-04-08 2015-01-08 4/A XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 10.000 10.000
2015-01-09 2015-01-08 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 10.000 10.000
2014-12-15 2014-12-11 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other -403.166 2.218.572 -15,38
2014-12-15 2014-06-02 4/A XLRN ACCELERON PHARMA INC
Common Stock
J - Other -198.005 2.621.738 -7,02
2014-08-18 2014-08-14 4 TRVN TREVENA INC
Common Stock
S - Sale -354 36.369 -0,96 6,04 -2.138 219.669
2014-08-18 2014-08-14 4 TRVN TREVENA INC
Common Stock
S - Sale -243 24.911 -0,97 6,04 -1.468 150.462
2014-08-18 2014-08-14 4 TRVN TREVENA INC
Common Stock
S - Sale -690 70.885 -0,96 6,04 -4.168 428.145
2014-08-18 2014-08-14 4 TRVN TREVENA INC
Common Stock
S - Sale -35.415 3.637.115 -0,96 6,04 -213.907 21.968.175
2014-08-15 2014-08-13 4 TRVN TREVENA INC
Common Stock
S - Sale -55 36.723 -0,15 6,12 -337 224.745
2014-08-15 2014-08-13 4 TRVN TREVENA INC
Common Stock
S - Sale -38 25.154 -0,15 6,12 -233 153.942
2014-08-15 2014-08-13 4 TRVN TREVENA INC
Common Stock
S - Sale -107 71.575 -0,15 6,12 -655 438.039
2014-08-15 2014-08-13 4 TRVN TREVENA INC
Common Stock
S - Sale -5.500 3.672.530 -0,15 6,12 -33.660 22.475.884
2014-07-11 2014-07-09 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 29.117 29.117
2014-07-11 2014-07-09 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other -29.117 2.915 -90,90
2014-06-05 2014-06-03 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 19.778 32.032 161,40
2014-05-15 2014-05-14 4 TRVN TREVENA INC
Stock Option (Right to Buy)
A - Award 8.870 8.870
2014-05-07 2014-05-05 4 XLRN ACCELERON PHARMA INC
Common Stock
S - Sale -313.491 2.819.743 -10,01 42,86 -13.436.224 120.854.185
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series C Preferred Stock
C - Conversion -4.840.686 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B-1 Preferred Stock
C - Conversion -1.462.868 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B-1 Preferred Stock
S - Sale -487.132 62.868 -88,57 1,13 -549.972 70.978
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B-1 Preferred Stock
X - Other 550.000 550.000 1,00 550.000 550.000
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Warrants- Purchase Series B-1 Preferred Stock (right to buy)
X - Other -550.000 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series B Preferred Stock
C - Conversion -8.400.000 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Series A Preferred Stock
C - Conversion -6.000.000 0 -100,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Common Stock
P - Purchase 472.405 3.811.682 14,15 7,00 3.306.835 26.681.774
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Common Stock
C - Conversion 780.754 3.339.277 30,52
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Common Stock
C - Conversion 235.946 2.558.523 10,16
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Common Stock
C - Conversion 1.354.837 2.322.577 140,00
2014-02-07 2014-02-05 4 TRVN TREVENA INC
Common Stock
C - Conversion 967.740 967.740
2014-01-30 3 TRVN TREVENA INC
Common Stock
0
2014-01-03 2014-01-02 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
A - Award 9.339 12.254 320,38
2013-12-09 2013-12-05 4 XLRN ACCELERON PHARMA INC
Option to Purchase Common Stock
A - Award 20.000 20.000
2013-11-08 2013-11-07 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
S - Sale -2.026 0 -100,00 9,11 -18.457
2013-11-08 2013-11-07 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
S - Sale -57 0 -100,00 9,11 -519
2013-11-08 2013-11-06 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 106 1.626 6,97
2013-11-08 2013-11-06 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 186 2.915 6,82
2013-10-28 2013-10-24 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 150 1.520 10,95
2013-10-28 2013-10-24 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 259 2.729 10,49
2013-09-27 2013-09-25 4 BIND BIND Therapeutics, Inc
Series D Preferred Stock
C - Conversion -964.798 0 -100,00
2013-09-27 2013-09-25 4 BIND BIND Therapeutics, Inc
Series C-1 Preferred Stock
C - Conversion -390.170 0 -100,00
2013-09-27 2013-09-25 4 BIND BIND Therapeutics, Inc
Series C Preferred Stock
C - Conversion -487.780 0 -100,00
2013-09-27 2013-09-25 4 BIND BIND Therapeutics, Inc
Series B Preferred Stock
C - Conversion -1.900.000 0 -100,00
2013-09-27 2013-09-25 4 BIND BIND Therapeutics, Inc
Series A Preferred Stock
C - Conversion -1.476.960 0 -100,00
2013-09-27 2013-09-25 4 BIND BIND Therapeutics, Inc
Common Stock
P - Purchase 26.000 2.018.253 1,31 15,00 390.000 30.273.795
2013-09-27 2013-09-25 4 BIND BIND Therapeutics, Inc
Common Stock
C - Conversion 1.992.253 1.992.253
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series F Convertible Preferred Stock
C - Conversion -95.541 0 -100,00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series E Convertible Preferred Stock
J - Other -172.188 0 -100,00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series D Convertible Preferred Stock
C - Conversion -48.577 0 -100,00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series C Convertible Preferred Stock
C - Conversion -363.495 0 -100,00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series B Convertible Preferred Stock
C - Conversion -629.499 0 -100,00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Series A Convertible Preferred Stock
C - Conversion -1.706.532 0 -100,00
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock
C - Conversion 95.541 3.133.234 3,15
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock
J - Other 277.520 3.037.693 10,05
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock
C - Conversion 48.577 2.760.173 1,79
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock
C - Conversion 363.495 2.711.596 15,48
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock
C - Conversion 629.499 2.348.101 36,63
2013-09-26 2013-09-24 4 XLRN ACCELERON PHARMA INC
Common Stock
C - Conversion 1.706.532 1.718.602 14.138,62
2013-09-18 3 XLRN ACCELERON PHARMA INC
Common Stock
12.070
2013-08-16 2013-08-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 136 1.370 11,02
2013-08-16 2013-08-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 247 2.470 11,11
2013-08-01 2013-07-30 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 136 1.234 12,39
2013-08-01 2013-07-30 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 247 2.223 12,50
2013-07-19 2013-07-17 4 ALIM ALIMERA SCIENCES INC
Common Stock
S - Sale -120.664 3.090.769 -3,76 4,80 -579.646 14.847.436
2013-07-19 2013-07-17 4 ALIM ALIMERA SCIENCES INC
Common Stock
S - Sale -2.273 57.586 -3,80 4,80 -10.919 276.632
2013-06-19 2013-06-18 4 ALIM ALIMERA SCIENCES INC
Common Stock
S - Sale -16.630 3.211.433 -0,52 5,46 -90.823 17.538.920
2013-06-19 2013-06-18 4 ALIM ALIMERA SCIENCES INC
Common Stock
S - Sale -313 59.859 -0,52 5,46 -1.709 326.914
2013-06-19 2013-06-17 4 ALIM ALIMERA SCIENCES INC
Common Stock
S - Sale -19.748 3.228.063 -0,61 5,42 -107.054 17.499.330
2013-06-19 2013-06-17 4 ALIM ALIMERA SCIENCES INC
Common Stock
S - Sale -372 60.172 -0,61 5,42 -2.017 326.192
2013-06-17 2013-06-13 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 136 1.098 14,14
2013-06-17 2013-06-13 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 247 1.976 14,29
2013-06-05 2013-06-03 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 136 962 16,46
2013-06-05 2013-06-03 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 247 1.729 16,67
2012-12-05 2012-12-04 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 143 826 20,94
2012-12-05 2012-12-04 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 247 1.482 20,00
2012-11-19 2012-11-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 136 683 24,86
2012-11-19 2012-11-15 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 247 1.235 25,00
2012-09-17 2012-09-13 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 136 547 33,09
2012-09-17 2012-09-13 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
J - Other 247 988 33,33
2010-02-02 3 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
40.000
2010-02-02 3 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
163.302
2010-02-02 3 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
6.100.678
2005-02-24 2004-12-16 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -104 37.074 -0,28 6,75 -702 250.250
2005-02-24 2004-12-16 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -6.724 2.351.376 -0,29 6,75 -45.387 15.871.788
2005-02-24 2004-12-16 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -172 61.080 -0,28 6,75 -1.161 412.290
2005-02-04 2005-02-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -1.268 30.384 -4,01 7,41 -9.396 225.145
2005-02-04 2005-02-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -81.647 1.938.532 -4,04 7,41 -605.004 14.364.522
2005-02-04 2005-02-02 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -2.085 50.076 -4,00 7,41 -15.450 371.063
2005-02-02 2005-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -596 31.652 -1,85 7,18 -4.279 227.261
2005-02-02 2005-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -38.422 2.020.179 -1,87 7,18 -275.870 14.504.885
2005-02-02 2005-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -982 52.161 -1,85 7,18 -7.051 374.516
2005-02-02 2005-01-31 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -358 32.248 -1,10 7,00 -2.506 225.736
2005-02-02 2005-01-31 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -23.053 2.058.601 -1,11 7,00 -161.371 14.410.207
2005-02-02 2005-01-31 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -589 53.143 -1,10 7,00 -4.123 372.001
2005-01-27 2005-01-26 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -298 32.606 -0,91 7,09 -2.113 231.177
2005-01-27 2005-01-26 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -19.211 2.081.654 -0,91 7,09 -136.206 14.758.927
2005-01-27 2005-01-26 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -491 53.732 -0,91 7,09 -3.481 380.960
2005-01-27 2005-01-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -298 32.904 -0,90 7,16 -2.134 235.593
2005-01-27 2005-01-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -19.211 2.100.865 -0,91 7,16 -137.551 15.042.193
2005-01-27 2005-01-25 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -491 54.223 -0,90 7,16 -3.516 388.237
2005-01-25 2005-01-21 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -339 33.202 -1,01 7,58 -2.570 251.671
2005-01-25 2005-01-21 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -21.898 2.102.111 -1,03 7,58 -165.987 15.934.001
2005-01-25 2005-01-21 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -562 54.714 -1,02 7,58 -4.260 414.732
2005-01-21 2005-01-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -127 33.541 -0,38 7,63 -969 255.918
2005-01-21 2005-01-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -8.165 2.124.009 -0,38 7,63 -62.299 16.206.189
2005-01-21 2005-01-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -208 55.276 -0,37 7,63 -1.587 421.756
2005-01-21 2005-01-19 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -746 33.668 -2,17 7,74 -5.774 260.590
2005-01-21 2005-01-19 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -48.028 2.132.174 -2,20 7,74 -371.737 16.503.027
2005-01-21 2005-01-19 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -1.226 55.484 -2,16 7,74 -9.489 429.446
2005-01-19 2005-01-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -164 34.414 -0,47 8,54 -1.401 293.896
2005-01-19 2005-01-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -10.566 2.180.202 -0,48 8,54 -90.234 18.618.925
2005-01-19 2005-01-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -270 56.710 -0,47 8,54 -2.306 484.303
2005-01-19 2005-01-14 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -205 34.578 -0,59 8,77 -1.798 303.249
2005-01-19 2005-01-14 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -13.160 2.190.768 -0,60 8,77 -115.413 19.213.035
2005-01-19 2005-01-14 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -335 56.980 -0,58 8,77 -2.938 499.715
2005-01-10 2005-01-06 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -373 34.783 -1,06 8,30 -3.096 288.699
2005-01-10 2005-01-06 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -24.014 2.203.928 -1,08 8,30 -199.316 18.292.602
2005-01-10 2005-01-06 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -613 57.315 -1,06 8,30 -5.088 475.714
2005-01-06 2005-01-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -694 35.156 -1,94 7,68 -5.330 269.998
2005-01-06 2005-01-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -44.665 2.227.942 -1,97 7,68 -343.027 17.110.595
2005-01-06 2005-01-04 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -1.141 57.928 -1,93 7,68 -8.763 444.887
2005-01-04 2005-01-03 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -746 35.850 -2,04 7,63 -5.692 273.536
2005-01-04 2005-01-03 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -48.028 2.272.607 -2,07 7,63 -366.454 17.339.991
2005-01-04 2005-01-03 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -1.226 59.069 -2,03 7,63 -9.354 450.696
2004-12-30 2004-12-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -90 36.596 -0,25 7,56 -680 276.666
2004-12-30 2004-12-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -5.764 2.320.635 -0,25 7,56 -43.576 17.544.001
2004-12-30 2004-12-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -147 60.295 -0,24 7,56 -1.111 455.830
2004-12-30 2004-12-28 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -97 36.686 -0,26 7,56 -733 277.346
2004-12-30 2004-12-28 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -6.244 2.326.399 -0,27 7,56 -47.205 17.587.576
2004-12-30 2004-12-28 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -159 60.442 -0,26 7,56 -1.202 456.942
2004-12-21 2004-12-17 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -395 36.783 -1,06 6,69 -2.644 246.189
2004-12-21 2004-12-17 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -25.455 2.332.643 -1,08 6,69 -170.370 15.612.380
2004-12-21 2004-12-17 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -650 60.601 -1,06 6,69 -4.350 405.602
2004-12-21 2004-12-10 4/A ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -552 39.662 -1,37 6,76 -3.730 267.996
2004-12-21 2004-12-10 4/A ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -35.540 2.518.030 -1,39 6,76 -240.144 17.014.329
2004-12-21 2004-12-10 4/A ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -908 65.335 -1,37 6,76 -6.135 441.469
2004-12-21 2004-12-14 4/A ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -2.484 37.178 -6,26 6,52 -16.188 242.289
2004-12-21 2004-12-14 4/A ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -159.932 2.358.098 -6,35 6,52 -1.042.277 15.367.725
2004-12-21 2004-12-14 4/A ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -4.084 61.251 -6,25 6,52 -26.615 399.173
2004-12-16 2004-12-14 4 ALNY POLARIS INDUSTRIES INC/MN
Common Stock
S - Sale -2.484 37.178 -6,26 6,52 -16.188 242.289
2004-12-16 2004-12-14 4 ALNY POLARIS INDUSTRIES INC/MN
Common Stock
S - Sale -159.932 2.358.098 -6,35 6,52 -1.042.277 15.367.725
2004-12-16 2004-12-14 4 ALNY POLARIS INDUSTRIES INC/MN
Common Stock
S - Sale -4.084 61.251 -6,25 6,52 -26.615 399.173
2004-12-14 2004-12-10 4 ALNY POLARIS INDUSTRIES INC/MN
Common Stock
S - Sale -552 39.662 -1,37 6,76 -3.730 267.996
2004-12-14 2004-12-10 4 ALNY POLARIS INDUSTRIES INC/MN
Common Stock
S - Sale -35.540 2.518.030 -1,39 6,76 -240.144 17.014.329
2004-12-14 2004-12-10 4 ALNY POLARIS INDUSTRIES INC/MN
Common Stock
S - Sale -908 65.335 -1,37 6,76 -6.135 441.469
2004-12-10 2004-12-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -589 40.214 -1,44 6,85 -4.037 275.627
2004-12-10 2004-12-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -37.942 2.553.570 -1,46 6,85 -260.054 17.502.169
2004-12-10 2004-12-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -969 66.243 -1,44 6,85 -6.642 454.030
2004-12-10 2004-12-08 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -351 40.803 -0,85 6,93 -2.431 282.642
2004-12-10 2004-12-08 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -22.573 2.591.512 -0,86 6,93 -156.363 17.951.404
2004-12-10 2004-12-08 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -576 67.212 -0,85 6,93 -3.990 465.578
2004-12-07 2004-12-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -312 41.154 -0,75 7,00 -2.183 287.996
2004-12-07 2004-12-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -21.179 2.614.085 -0,80 7,00 -148.211 18.293.367
2004-12-07 2004-12-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -509 67.788 -0,75 7,00 -3.562 474.380
2004-12-07 2004-12-03 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -1.180 41.466 -2,77 6,74 -7.957 279.605
2004-12-07 2004-12-03 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -74.876 2.635.264 -2,76 6,74 -504.889 17.769.585
2004-12-07 2004-12-03 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -1.944 68.297 -2,77 6,74 -13.108 460.527
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)